UY29979A1 - Derivados espirociclicos - Google Patents
Derivados espirociclicosInfo
- Publication number
- UY29979A1 UY29979A1 UY29979A UY29979A UY29979A1 UY 29979 A1 UY29979 A1 UY 29979A1 UY 29979 A UY29979 A UY 29979A UY 29979 A UY29979 A UY 29979A UY 29979 A1 UY29979 A1 UY 29979A1
- Authority
- UY
- Uruguay
- Prior art keywords
- spirociclic
- derivatives
- single bond
- alkyl group
- pain
- Prior art date
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 1
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 abstract 1
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La invención proporciona compuestos de fórmula (I): en la que : m es 0,1 ó 2 X es O, S o N-CN R es F, CI o CN; A es un grupo cicloalquileno C3-6 opcionalmente sustituido con un grupo alquilo C1-4; y B es un enlace sencillo o un grupo alquilo C1-4; y B es un enlace sencillo o un grupo alquileno C1-2; o una de sus sales, solvatos, polimorfismos o profármacos farmacéuticamente aceptable. Los compuestos son inhibidores de PDE7 y tienen una diversidad de aplicaciones terapéuticas, particularmente en el tratamiento del dolor, especialmente dolor neuropático.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74185405P | 2005-12-02 | 2005-12-02 | |
| US79118606P | 2006-04-10 | 2006-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY29979A1 true UY29979A1 (es) | 2007-06-29 |
Family
ID=37882213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY29979A UY29979A1 (es) | 2005-12-02 | 2006-11-30 | Derivados espirociclicos |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7507742B2 (es) |
| EP (1) | EP1957467A2 (es) |
| JP (1) | JP2009517453A (es) |
| KR (1) | KR101009554B1 (es) |
| AP (1) | AP2008004470A0 (es) |
| AR (1) | AR058266A1 (es) |
| AU (1) | AU2006321349A1 (es) |
| BR (1) | BRPI0619126A2 (es) |
| CA (1) | CA2631535C (es) |
| CR (1) | CR10039A (es) |
| EA (1) | EA200801145A1 (es) |
| EC (1) | ECSP088484A (es) |
| GT (1) | GT200600494A (es) |
| MA (1) | MA30014B1 (es) |
| ME (1) | MEP0408A (es) |
| NL (1) | NL2000336C2 (es) |
| NO (1) | NO20082077L (es) |
| PE (1) | PE20071087A1 (es) |
| RS (1) | RS20080233A (es) |
| TW (1) | TW200732307A (es) |
| UY (1) | UY29979A1 (es) |
| WO (1) | WO2007063391A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU714980B2 (en) | 1996-07-24 | 2000-01-13 | Warner-Lambert Company Llc | Isobutylgaba and its derivatives for the treatment of pain |
| BRPI0609879A2 (pt) * | 2005-04-28 | 2010-05-11 | Pfizer Ltd | derivados de aminoácidos |
| MX2009010450A (es) * | 2007-03-27 | 2009-11-23 | Omeros Corp | El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento. |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| JP2010527986A (ja) * | 2007-05-24 | 2010-08-19 | ファイザー・リミテッド | スピロ環状キナゾリン誘導体およびｐｄｅ７阻害剤としてのその使用 |
| SG157299A1 (en) * | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| WO2010135468A1 (en) * | 2009-05-19 | 2010-11-25 | Vivia Biotech S.L. | Methods for providing personalized medicine tests ex vivo for hematological neoplasms |
| CA2817071C (en) | 2010-11-08 | 2018-04-24 | Omeros Corporation | Treatment of addiction and impulse-control disorders using pde7 inhibitors |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| KR102640696B1 (ko) * | 2017-07-12 | 2024-02-27 | 다트 뉴로사이언스, 엘엘씨 | Pde7 억제제로서 치환된 벤즈옥사졸 및 벤조푸란 화합물 |
| EP4572766A1 (en) | 2022-08-18 | 2025-06-25 | Mitodicure GmbH | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001083772A1 (en) | 2000-04-28 | 2001-11-08 | Merck Patent Gmbh | Splice variant of camp phosphodiesterase type 7 (pde7a3) |
| WO2002076953A1 (en) | 2001-03-21 | 2002-10-03 | Warner-Lambert Company Llc | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| WO2006092692A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| MX2007010721A (es) * | 2005-03-01 | 2007-11-13 | Pfizer Ltd | Nuevo uso de inhibidores de fosfodiesterasa 7 para el tratamiento de dolor neuropatico. |
-
2006
- 2006-11-23 ME MEP-04/08A patent/MEP0408A/xx unknown
- 2006-11-23 AU AU2006321349A patent/AU2006321349A1/en not_active Abandoned
- 2006-11-23 EP EP06820991A patent/EP1957467A2/en not_active Withdrawn
- 2006-11-23 AP AP2008004470A patent/AP2008004470A0/xx unknown
- 2006-11-23 BR BRPI0619126-6A patent/BRPI0619126A2/pt not_active Application Discontinuation
- 2006-11-23 KR KR1020087013205A patent/KR101009554B1/ko not_active Expired - Fee Related
- 2006-11-23 RS RSP-2008/0233A patent/RS20080233A/sr unknown
- 2006-11-23 EA EA200801145A patent/EA200801145A1/xx unknown
- 2006-11-23 JP JP2008542855A patent/JP2009517453A/ja not_active Withdrawn
- 2006-11-23 WO PCT/IB2006/003388 patent/WO2007063391A2/en not_active Ceased
- 2006-11-23 CA CA2631535A patent/CA2631535C/en not_active Expired - Fee Related
- 2006-11-27 NL NL2000336A patent/NL2000336C2/nl not_active IP Right Cessation
- 2006-11-29 GT GT200600494A patent/GT200600494A/es unknown
- 2006-11-29 PE PE2006001519A patent/PE20071087A1/es not_active Application Discontinuation
- 2006-11-30 UY UY29979A patent/UY29979A1/es not_active Application Discontinuation
- 2006-12-01 US US11/565,953 patent/US7507742B2/en not_active Expired - Fee Related
- 2006-12-01 TW TW095144665A patent/TW200732307A/zh unknown
- 2006-12-01 AR ARP060105332A patent/AR058266A1/es unknown
-
2008
- 2008-05-02 NO NO20082077A patent/NO20082077L/no not_active Application Discontinuation
- 2008-05-29 EC EC2008008484A patent/ECSP088484A/es unknown
- 2008-05-30 CR CR10039A patent/CR10039A/es not_active Application Discontinuation
- 2008-06-02 MA MA30981A patent/MA30014B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR10039A (es) | 2008-07-10 |
| NO20082077L (no) | 2008-06-04 |
| CA2631535A1 (en) | 2007-06-07 |
| WO2007063391A2 (en) | 2007-06-07 |
| KR101009554B1 (ko) | 2011-01-18 |
| AR058266A1 (es) | 2008-01-30 |
| MA30014B1 (fr) | 2008-12-01 |
| RS20080233A (sr) | 2009-07-15 |
| US7507742B2 (en) | 2009-03-24 |
| US20070129388A1 (en) | 2007-06-07 |
| BRPI0619126A2 (pt) | 2011-09-13 |
| ECSP088484A (es) | 2008-06-30 |
| MEP0408A (xx) | 2010-02-10 |
| CA2631535C (en) | 2010-07-27 |
| JP2009517453A (ja) | 2009-04-30 |
| KR20080059338A (ko) | 2008-06-26 |
| EP1957467A2 (en) | 2008-08-20 |
| GT200600494A (es) | 2007-07-06 |
| AU2006321349A1 (en) | 2007-06-07 |
| WO2007063391A3 (en) | 2007-09-13 |
| AP2008004470A0 (en) | 2008-06-30 |
| PE20071087A1 (es) | 2007-12-29 |
| TW200732307A (en) | 2007-09-01 |
| NL2000336A1 (nl) | 2007-06-05 |
| NL2000336C2 (nl) | 2007-08-07 |
| EA200801145A1 (ru) | 2008-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP088484A (es) | Derivados de quinazolina espirocíclicos como inhibidores de pde7 | |
| CY1110498T1 (el) | Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα | |
| BG108181A (bg) | Нови спиротрициклични производни и тяхното използване като инхибитори на фосфодиестераза-7 | |
| CY1109732T1 (el) | Χρησις παραγωγων βενζο-συνενωμενου ετεροκυκλο σουλφαμιδιου δια την θεραπειαν πονου | |
| UY26380A1 (es) | Inhibidores de fab i | |
| ECSP034914A (es) | "azaindoles" | |
| ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
| EA201000563A1 (ru) | Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i | |
| PE20110062A1 (es) | N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo | |
| NO20052787L (no) | N-alkyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler | |
| ECSP034642A (es) | Derivados de tetralona como agentes antitumorales | |
| CY1111613T1 (el) | Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv | |
| NI200700320A (es) | Inhibidores de la actividad akt | |
| NO20073783L (no) | Pyrrolidininhibitorer for IAP | |
| EA200500399A1 (ru) | Ненуклеозидные ингибиторы обратной транскриптазы | |
| PA8548001A1 (es) | Derivados aromaticos de acidos dicarboxilicos | |
| ATE548034T1 (de) | Pharmazeutische zusammensetzungen mit droxidopa | |
| DE60221684D1 (de) | Antibiotika mit doppelwirkung | |
| CY1109529T1 (el) | 2-(αμινο-υποκατεστημενες)-4-αρυλο πυραμιδινες και σχετικες ενωσεις που χρησιμευουν στην αγωγη φλεγμονωδων νοσηματων | |
| BRPI0418384A (pt) | composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes | |
| DK1709044T4 (da) | Oxazolidinon-quinolon-hybridantibiotika | |
| DE602006013191D1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
| ECSP055745A (es) | Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona | |
| DE60105025D1 (de) | Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie | |
| HRP20090159T1 (en) | Use of glucosidase inhibitors for therapy of mucovisidosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20161213 |